1. A 25 mg rectal dose of diclofenac for prevention of post-ERCP pancreatitis in elderly patients
- Author
-
Yoshihiro Nakamura, Hirotsugu Maruyama, Masami Nakatani, Daisuke Ikeda, Akira Higashimori, Yuki Mizuno, Takashi Fukuda, Yasuhiro Fujiwara, Kenichi Morimoto, Natsumi Maeda, and Toshio Watanabe
- Subjects
medicine.medical_specialty ,Diclofenac ,NSAIDs ,Indomethacin ,elderly patients ,Gastroenterology ,ジクロフェナク ,Inverse probability of treatment weighting ,Internal medicine ,medicine ,Humans ,post-endoscopic retrograde cholangiopancreatography pancreatitis ,inverse probability of treatment weighting ,Aged ,Retrospective Studies ,Cholangiopancreatography, Endoscopic Retrograde ,business.industry ,medicine.disease ,stomatognathic diseases ,Pancreatitis ,Post ercp pancreatitis ,business ,medicine.drug - Abstract
Objectives: A 50–100 mg rectal dose of diclofenac or indomethacin is recommended for prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP); however, limited data are available regarding the appropriate dose to prevent PEP in elderly patients. We aimed to evaluate the efficacy and safety of 25 mg diclofenac in preventing PEP in elderly patients. ......
- Published
- 2021
- Full Text
- View/download PDF